NO20073063L - Monoklonale antistoff mot NKG2A - Google Patents

Monoklonale antistoff mot NKG2A

Info

Publication number
NO20073063L
NO20073063L NO20073063A NO20073063A NO20073063L NO 20073063 L NO20073063 L NO 20073063L NO 20073063 A NO20073063 A NO 20073063A NO 20073063 A NO20073063 A NO 20073063A NO 20073063 L NO20073063 L NO 20073063L
Authority
NO
Norway
Prior art keywords
disorders
nkg2a
monoclonal antibody
compounds
treating
Prior art date
Application number
NO20073063A
Other languages
English (en)
Other versions
NO346624B1 (no
Inventor
Pascale Andre
Alessandro Moretta
Emanuela Marcenaro
Francois Romagne
Original Assignee
Innate Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36350427&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20073063(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innate Pharma Sa filed Critical Innate Pharma Sa
Publication of NO20073063L publication Critical patent/NO20073063L/no
Publication of NO346624B1 publication Critical patent/NO346624B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)

Abstract

Sammendrag Det beskrives fremgangsmåter for å behandle immunforstyrrelser, spesielt autoimmune eller inflammatoriske forstyrrelser, og fremgangsmåter for å produsere antistoff og andre forbindelser for anvendelse i terapeutiske strategier for å behandle slike forstyrrelser. Generelt, foreliggende oppfinnelse involverer anvendelse av antistoff eller andre forbindelser som hindrer stimulering av NKG2A reseptorer på NK-celler, som fører til lysering av dendritiske celler som bidrar til patologien av forstyrrelsene.
NO20073063A 2004-12-28 2005-12-27 Monoklonale antistoff mot NKG2A NO346624B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63946504P 2004-12-28 2004-12-28
US63983204P 2004-12-28 2004-12-28
PCT/IB2005/004013 WO2006070286A2 (en) 2004-12-28 2005-12-27 Monoclonal antibodies against nkg2a

Publications (2)

Publication Number Publication Date
NO20073063L true NO20073063L (no) 2007-09-28
NO346624B1 NO346624B1 (no) 2022-11-07

Family

ID=36350427

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073063A NO346624B1 (no) 2004-12-28 2005-12-27 Monoklonale antistoff mot NKG2A

Country Status (19)

Country Link
US (5) US8993319B2 (no)
EP (3) EP2476705B1 (no)
JP (2) JP5721304B2 (no)
KR (1) KR101564713B1 (no)
CN (1) CN102977213B (no)
AU (1) AU2005321017B2 (no)
BR (1) BRPI0519420A2 (no)
CA (1) CA2591059C (no)
DK (2) DK2476705T3 (no)
ES (2) ES2557587T3 (no)
FI (1) FI1831258T4 (no)
HK (1) HK1108458A1 (no)
HU (2) HUE026107T2 (no)
IL (1) IL184152A (no)
MX (1) MX2007007935A (no)
NO (1) NO346624B1 (no)
PT (2) PT1831258E (no)
RU (1) RU2481356C2 (no)
WO (1) WO2006070286A2 (no)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101325023B1 (ko) 2003-07-02 2013-11-04 노보 노르디스크 에이/에스 Ｎｋ 세포 활성을 조절하기 위한 조성물 및 방법
KR101564713B1 (ko) 2004-12-28 2015-11-06 이나뜨 파르마 Ｎｋｇ2ａ에 대한 단클론 항체
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
CN101300272B (zh) 2005-10-14 2013-09-18 依奈特制药公司 用于治疗增生性病症的组合物和方法
KR101239051B1 (ko) 2005-10-21 2013-03-04 추가이 세이야쿠 가부시키가이샤 심장질환 치료제
EP3345616A1 (en) 2006-03-31 2018-07-11 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
JP5624276B2 (ja) 2006-03-31 2014-11-12 中外製薬株式会社 抗体の血中動態を制御する方法
CA2648644C (en) 2006-04-07 2016-01-05 Osaka University Muscle regeneration promoter
AR061317A1 (es) 2006-06-08 2008-08-20 Chugai Pharmaceutical Co Ltd Agentes para prevenir o tratar enfermedades inflamatorias
JP5829004B2 (ja) 2006-06-30 2015-12-09 ノボ・ノルデイスク・エー／エス 抗ｎｋｇ２ａ抗体とその使用
US8057795B2 (en) * 2006-11-21 2011-11-15 Children's Research Institute Method of reducing the activation of Th2 lymphocytes
CN101646459B (zh) 2007-01-23 2014-02-12 国立大学法人信州大学 慢性排斥反应抑制剂
KR102225009B1 (ko) 2007-09-26 2021-03-08 추가이 세이야쿠 가부시키가이샤 항체 정상영역 개변체
JP5334319B2 (ja) 2007-09-26 2013-11-06 中外製薬株式会社 Ｃｄｒのアミノ酸置換により抗体の等電点を改変する方法
PE20140132A1 (es) * 2007-09-26 2014-02-14 Chugai Pharmaceutical Co Ltd Anticuerpo anti-receptor de il-6
TWI441649B (zh) 2007-12-05 2014-06-21 Chugai Pharmaceutical Co Ltd Use of anti-NR10 monoclonal antibody with neutralizing activity against NR10 in the manufacture of prophylactic or therapeutic agents for pruritus
BRPI0821110B8 (pt) * 2007-12-05 2021-05-25 Chugai Pharmaceutical Co Ltd anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
MX2010007935A (es) * 2008-01-24 2010-08-23 Novo Nordisk As Anticuerpo monoclonal humanizado anti-nkg2a humano.
KR20220162801A (ko) 2008-04-11 2022-12-08 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
WO2009148148A1 (ja) 2008-06-05 2009-12-10 国立がんセンター総長が代表する日本国 神経浸潤抑制剤
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
KR20160062207A (ko) * 2008-12-05 2016-06-01 추가이 세이야쿠 가부시키가이샤 항ｎｒ１０ 항체 및 그의 이용
JP2010210772A (ja) * 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
EP2409991B1 (en) 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
EP2409990A4 (en) 2009-03-19 2013-01-23 Chugai Pharmaceutical Co Ltd VARIANT OF A CONSTANT ANTIBODY REGION
KR101314880B1 (ko) * 2009-03-19 2013-10-04 추가이 세이야쿠 가부시키가이샤 관절류머티즘 치료제
US10150808B2 (en) * 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
JP2013520476A (ja) 2010-02-26 2013-06-06 ノヴォ ノルディスク アー／エス 安定な抗体含有組成物
EP2543730B1 (en) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
HRP20221490T1 (hr) 2010-05-28 2023-02-03 Chugai Seiyaku Kabushiki Kaisha Poboljšanje antitumorskog odgovora t stanice
EP2588498B1 (en) 2010-06-29 2018-07-11 Centre National de la Recherche Scientifique (CNRS) Llt-1 antibodies with new functional properties
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
TWI560200B (en) * 2011-05-25 2016-12-01 Innate Pharma Sa Anti-kir antibodies for the treatment of inflammatory and autoimmune disorders
MX342131B (es) * 2011-06-17 2016-09-14 Novo Nordisk As Eliminacion selectiva de celulas erosivas.
EP3009518B1 (en) 2013-06-11 2020-08-12 National Center of Neurology and Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy
WO2015046467A1 (ja) 2013-09-27 2015-04-02 中外製薬株式会社 ポリペプチド異種多量体の製造方法
KR20170051462A (ko) * 2014-08-28 2017-05-11 아카데미슈 지켄후이스 라이덴 Ｃｄ９４／ｎｋｇ２ａ 및／또는 ｃｄ９４／ｎｋｇ２ｂ 항체, 백신 조합물
EP3799885A1 (en) 2014-09-16 2021-04-07 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
WO2016041947A1 (en) 2014-09-16 2016-03-24 Innate Pharma Treatment regimens using anti-nkg2a antibodies
SG11201701388UA (en) * 2014-10-23 2017-03-30 Innate Pharma Treatment of cancers using anti-nkg2a agents
EP4269440A3 (en) 2015-02-27 2024-02-28 Chugai Seiyaku Kabushiki Kaisha Composition for treating il-6-related diseases
WO2016149103A1 (en) * 2015-03-13 2016-09-22 The Regents Of The University Of California Monoclonal antibody for prevention and/or treatment of astrovirus disease
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
BR112017022101A2 (pt) 2015-04-14 2018-07-31 Chugai Seiyaku Kabushiki Kaisha composição farmacêutica para prevenção e/ou tratamento de dermatite atópica contendo antagonista de il-31 como ingrediente ativo
WO2016186154A1 (ja) 2015-05-19 2016-11-24 国立研究開発法人国立精神・神経医療研究センター 多発性硬化症（ｍｓ）患者の新規治療適用判断方法
EP3325967B1 (en) 2015-07-24 2019-12-04 Innate Pharma Methods for detecting tissue infiltrating nk cells
BR112018009312A8 (pt) 2015-12-28 2019-02-26 Chugai Pharmaceutical Co Ltd método para promover eficiência de purificação de polipeptídeo contendo região de fc
CN108884163B (zh) 2016-01-21 2022-08-16 依奈特制药公司 对淋巴细胞中抑制途径的中和
DE102017001875A1 (de) * 2017-02-27 2018-08-30 Wolfgang Würfel Medikament zur Malignombehandlung
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
KR20200074160A (ko) 2017-10-20 2020-06-24 가꼬우호우징 효고 이카다이가쿠 항il-6 수용체 항체를 함유하는 수술 후의 유착을 억제하기 위한 의약 조성물
TW202003582A (zh) 2018-03-13 2020-01-16 法商天賜製藥公司 頭頸癌之治療
AU2019236865A1 (en) 2018-03-23 2020-10-01 Bristol-Myers Squibb Company Antibodies against MICA and/or MICB and uses thereof
EP3878869A4 (en) * 2018-11-07 2023-04-19 Shanghai Hyamab Biotech Co., Ltd. NKG2A ANTIBODY, METHOD FOR PREPARATION AND USE
CN113316590A (zh) 2018-11-16 2021-08-27 百时美施贵宝公司 抗nkg2a抗体及其用途
CN109833480B (zh) * 2019-03-22 2021-09-07 中国科学院上海巴斯德研究所 靶向nk细胞免疫检查点治疗感染性疾病的方法
EP3946455A4 (en) * 2019-03-29 2022-12-21 Dren Bio, Inc. METHOD OF REDUCING THE CONCENTRATION OF LARGE GRANULAR LYMPHOCYTES AND NATURAL KILLER CELLS
CN114127315A (zh) 2019-05-30 2022-03-01 百时美施贵宝公司 鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法
US20220233691A1 (en) 2019-05-30 2022-07-28 Bristol-Myers Squibb Company Cell localization signature and combination therapy
JP2022534967A (ja) 2019-05-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー 多腫瘍遺伝子シグネチャーおよびその使用
CA3144871A1 (en) 2019-06-27 2020-12-30 Crispr Therapeutics Ag Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer
AR120512A1 (es) 2019-11-20 2022-02-16 Chugai Pharmaceutical Co Ltd Formulaciones que contienen anticuerpos
WO2021260657A1 (en) 2020-06-26 2021-12-30 Crispr Therapeutics Ag Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
BR112023003553A2 (pt) 2020-08-31 2023-04-04 Bristol Myers Squibb Co Assinatura de localização celular e imunoterapia
CA3197662A1 (en) 2020-09-30 2022-04-07 Dren Bio, Inc. Anti-cd94 antibodies and methods of use thereof
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
EP4267172A1 (en) 2020-12-28 2023-11-01 Bristol-Myers Squibb Company Subcutaneous administration of pd1/pd-l1 antibodies
AU2021411486A1 (en) 2020-12-28 2023-06-29 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2024056010A1 (zh) * 2022-09-16 2024-03-21 北京三诺佳邑生物技术有限责任公司 特异性识别nkg2a的抗体及其应用
CN117143815B (zh) * 2023-10-30 2024-01-26 再少年(北京)生物科技有限公司 工程化记忆样nk细胞的制备方法及应用

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
FR2604092B1 (fr) 1986-09-19 1990-04-13 Immunotech Sa Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JPH03112485A (ja) 1989-09-22 1991-05-14 Olympus Optical Co Ltd Ｈｌａ―ｃ遺伝子およびｄｎａプローブ並びに形質転換細胞
JPH03112486A (ja) 1989-09-22 1991-05-14 Olympus Optical Co Ltd Ｈｌａ―ｂ３５遺伝子およびｄｎａプローブ並びに形質転換細胞
JPH03112487A (ja) 1989-09-22 1991-05-14 Olympus Optical Co Ltd ＨＬＡ―Ｂｗ５３遺伝子およびＤＮＡプローブ並びに形質転換細胞
JPH03112484A (ja) 1989-09-26 1991-05-14 Nisshin Seito Kk 新規制限酵素及びその製造方法
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
JP3112484B2 (ja) 1990-01-17 2000-11-27 テルモ株式会社 医療容器
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
JP3112487B2 (ja) 1990-10-12 2000-11-27 オリンパス光学工業株式会社 画像フリーズ用信号処理装置
JP3112485B2 (ja) 1991-01-22 2000-11-27 オリンパス光学工業株式会社 立体電子スチルカメラ
JP3112486B2 (ja) 1991-02-06 2000-11-27 大日本印刷株式会社 感圧複写紙
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US5489525A (en) 1992-10-08 1996-02-06 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies to prostate cells
DE614989T1 (de) * 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
US5539094A (en) 1993-11-12 1996-07-23 La Jolla Cancer Research Foundation DNA encoding Bcl-2-associated proteins
US5583034A (en) 1994-02-22 1996-12-10 La Jolla Institute For Allergy And Immunology Enhancement of adoptosis using antisense oligonucleotides
WO1996002576A1 (fr) 1994-07-13 1996-02-01 Chugai Seiyaku Kabushiki Kaisha Anticorps humain reconstitue contre l'interleukine-8 humaine
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
DE69737867T2 (de) 1996-05-03 2007-10-18 Immunomedics, Inc. Zielgerichtete kombinations-immuntherapie für krebs
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6750044B1 (en) 1996-10-17 2004-06-15 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
GB9725764D0 (en) 1997-12-04 1998-02-04 Isis Innovation HLA-E binding
NZ514918A (en) 1999-04-28 2003-11-28 Univ Texas Compositions and methods for cancer treatment by selectively inhibiting VEGF
WO2001036630A2 (en) 1999-11-15 2001-05-25 Innate Pharma S.A.S. Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells, and antibodies that identify the same
WO2001071005A2 (en) 2000-03-24 2001-09-27 Micromet Ag Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
US6999941B1 (en) 2000-07-11 2006-02-14 Amazon.Com, Inc. Providing gift clustering functionality to assist a user in ordering multiple items for a recipient
DK1343822T3 (da) * 2000-12-18 2012-08-13 Inst Nat Sante Rech Med Middel til diagnosticering og behandling af CTCL
US20030095965A1 (en) 2001-05-02 2003-05-22 Katrien Van Beneden Antibodies to Ly49E and CD94/NKG2 receptors
US7138243B2 (en) 2001-07-19 2006-11-21 Innate Pharma, S.A. NTB-A, a surface molecule involved in natural killer cells activity
US20030171280A1 (en) 2001-07-31 2003-09-11 Soderstrom Karl Petter Compositions and methods for modulation of immune responses
WO2003095965A2 (en) * 2002-05-13 2003-11-20 Envirotech Products Limited Tank valve testing method
EP1513554B9 (en) 2002-05-30 2011-11-09 Macrogenics, Inc. Cd16a binding proteins and use for the treatment of immune disorders
ATE328906T1 (de) 2002-06-28 2006-06-15 Domantis Ltd Dual-specifische liganden mit erhöhter halbwertszeit
EP1944320A1 (en) 2002-12-16 2008-07-16 Genentech, Inc. Immunoglobulin variants and uses thereof
CN1751236A (zh) 2002-12-16 2006-03-22 健泰科生物技术公司 表达人cd20的转基因小鼠
HUE033129T2 (en) 2003-07-24 2017-11-28 Innate Pharma Sa Methods and compositions for increasing the efficacy of therapeutic antibodies using compounds that potentiate NK cells
WO2005115517A2 (en) 2004-04-28 2005-12-08 Joslin Diabetes Center, Inc. Methods of treating diabetes
EP1740619A1 (en) 2004-04-30 2007-01-10 Innate Pharma Compositions and methods for treating proliferative disorders such as nk-type ldgl
CN101107269B (zh) 2004-12-28 2012-10-31 依奈特制药公司 抗nkg2a的单克隆抗体
KR101564713B1 (ko) 2004-12-28 2015-11-06 이나뜨 파르마 Ｎｋｇ2ａ에 대한 단클론 항체
JP3112486U (ja) 2005-05-13 2005-08-18 高北 孝 履物整頓具
JP3112484U (ja) 2005-05-13 2005-08-18 浩志 柯 熱交換器の構造
JP3112487U (ja) 2005-05-13 2005-08-18 株式会社國光社 手動式篩い器
CN101300272B (zh) 2005-10-14 2013-09-18 依奈特制药公司 用于治疗增生性病症的组合物和方法
JP5829004B2 (ja) 2006-06-30 2015-12-09 ノボ・ノルデイスク・エー／エス 抗ｎｋｇ２ａ抗体とその使用
MX2010007935A (es) 2008-01-24 2010-08-23 Novo Nordisk As Anticuerpo monoclonal humanizado anti-nkg2a humano.
JP2013520476A (ja) 2010-02-26 2013-06-06 ノヴォ ノルディスク アー／エス 安定な抗体含有組成物
MX342131B (es) 2011-06-17 2016-09-14 Novo Nordisk As Eliminacion selectiva de celulas erosivas.

Also Published As

Publication number Publication date
JP2013028640A (ja) 2013-02-07
EP3026063A1 (en) 2016-06-01
DK1831258T3 (en) 2016-01-11
US20190135938A1 (en) 2019-05-09
JP6054129B2 (ja) 2016-12-27
ES2557587T3 (es) 2016-01-27
EP1831258A2 (en) 2007-09-12
DK2476705T3 (en) 2015-12-14
HUE026688T2 (en) 2016-07-28
AU2005321017A1 (en) 2006-07-06
CN102977213B (zh) 2017-05-24
EP2476705B1 (en) 2015-10-07
WO2006070286A3 (en) 2006-08-31
AU2005321017A2 (en) 2006-07-06
CA2591059A1 (en) 2006-07-06
EP2476705A1 (en) 2012-07-18
US20150132316A1 (en) 2015-05-14
ES2557325T3 (es) 2016-01-25
DK1831258T4 (en) 2023-08-28
CN102977213A (zh) 2013-03-20
JP2008525520A (ja) 2008-07-17
MX2007007935A (es) 2007-12-06
NO346624B1 (no) 2022-11-07
IL184152A (en) 2015-03-31
FI1831258T4 (fi) 2023-08-31
BRPI0519420A2 (pt) 2009-01-20
PT2476705E (pt) 2016-02-09
EP1831258B1 (en) 2015-10-14
US8993319B2 (en) 2015-03-31
RU2481356C2 (ru) 2013-05-10
KR101564713B1 (ko) 2015-11-06
US10160810B2 (en) 2018-12-25
US20110229486A1 (en) 2011-09-22
HK1108458A1 (zh) 2008-05-09
RU2007129033A (ru) 2009-02-10
US20150125464A1 (en) 2015-05-07
CA2591059C (en) 2018-11-06
HUE026107T2 (en) 2016-05-30
ES2557325T5 (es) 2023-11-15
KR20070094945A (ko) 2007-09-27
EP1831258B2 (en) 2023-06-07
IL184152A0 (en) 2007-10-31
AU2005321017B2 (en) 2011-02-24
JP5721304B2 (ja) 2015-05-20
US20090208416A1 (en) 2009-08-20
WO2006070286A2 (en) 2006-07-06
PT1831258E (pt) 2016-01-07

Similar Documents

Publication Publication Date Title
NO20073063L (no) Monoklonale antistoff mot NKG2A
MA32982B1 (fr) Proteines de liaison au recepteur cgrp humain
EA200870130A1 (ru) Антитела против ил-6, предотвращающие связывание с gp130 комплекса ил-6 и альфа-рецептора ил-6
ATE469658T1 (de) Kombinationstherapien gegen multiple toll-like- rezeptoren und ihre verwendung
MX2023001727A (es) Anticuerpos anti-c5 y usos de los mismos.
MX2020007012A (es) Anticuerpos de union a gprc5d.
MX2021013681A (es) Moleculas de union a lag-3 y metodos de uso de las mismas.
WO2007042573A3 (en) Compositions and methods for treating proliferative disorders
CY1117702T1 (el) Πρωτεϊνες δεσμευομενες με αντιγονο ικανες να δεσμευονται με θυμικη στρωματικη λεμφοποιητινη
MX2010007935A (es) Anticuerpo monoclonal humanizado anti-nkg2a humano.
PE20070374A1 (es) ANTICUERPOS ANTI-MAdCAM
WO2021018859A3 (en) Antibodies binding to gprc5d
WO2003100033A3 (en) ANTI-αvβ6 ANTIBODIES
NO20092718L (no) Antagonist-anti-Notch 3-antistoffer og deres anvendelse i forebyggelsen og behandlingen av Notch 3-relaterte sykdommer
WO2019014328A3 (en) AGONISTIC ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF
EA200800812A1 (ru) Композиции антитела против cd3
NO20065252L (no) Behandling av forstyrrelser
UA94576C2 (ru) Выделенное антитело, которое связывается с igf-1r, композиция, которая его содержит, и способы, которые касаются антител
MX2020013122A (es) Anticuerpos biespecificos contra anticuerpos biespecíficos que se unen al antígeno carcinoembrionario humano (ceacam5) y grupo de diferenciación (cd47).
DE60333732D1 (de) Internalisierung von anti cd74 monoklonalen antikörpern und deren verwendungen
MX2009009194A (es) Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes.
NO20070153L (no) Loselig zcytorl4, anti-zcytorl4-antistoffer og bindingspartnere og fremgangsmater for anvendelse ved inflammasjon
UA96122C2 (ru) Антитело или его антигенсвязующий фрагмент, которое специфически связывается с il-22ra, и его применение
EP4253959A3 (en) Anti-idiotypic antibodies directed to the antigen-binding portion of an bcma-binding molecule
WO2021048564A3 (en) Antigen-binding domain